Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.33 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 2/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6123050 | 0.83 | GABRA1 (0.42) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL6123118 | 0.78 | GABRA1 (0.40) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL15239355 | 0.78 | GABRA1 (0.46) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL15239399 | 0.78 | GABRA1 (0.40) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL6122493 | 0.78 | GABRA1 (0.40) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL6122430 | 0.77 | GABRA1 (0.39) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL6121774 | 0.77 | GABRA1 (0.39) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL6122814 | 0.76 | GABRA1 (0.39) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL8564100 | 0.76 | NPY5R (0.40) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL6122545 | 0.75 | GABRG2 (0.58) | GABRA1GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3034079-B1 | PYRIDAZINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO INC (US) | 2018-01-10 | — | — | EP | disclosed |
| US-9801879-B2 | Pyridazine derivatives, compositions and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| EP-3034079-A1 | PYRIDAZINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | Agenebio, Inc. (US) | 2016-06-22 | — | — | EP | disclosed |
| US-20160008357-A1 | PYRIDAZINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. | 2016-01-14 | — | — | US | disclosed |
| EP-2640391-B1 | PYRIDAZINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO INC (US) | 2015-11-11 | — | — | EP | disclosed |
| US-9145372-B2 | Pyridazine derivatives, compositions and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| WO-2014153180-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | GALLAGHER MICHELA (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014078377-A1 | METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA | AGENEBIO, INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| EP-2640391-A1 | PYRIDAZINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | Agenebio, Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| US-20130237545-A1 | PYRIDAZINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| WO-2012068161-A1 | PYRIDAZINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237545-A1 | PYRIDAZINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GRM5, GRIK5, CHRNA5 | GABRA1 39/4885GABRG2 52/4885GABRB3 62/4885 |
| US-20160008357-A1 | PYRIDAZINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GRM5, GRIK5, CHRNA5 | GABRA1 39/4885GABRG2 52/4885GABRB3 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.